Anifrolumab for refractory autoimmune hemolytic anemia in SPENCD-associated lupus: a case-based review. (PubMed, ARP Rheumatol) - Oct 12, 2026 - "Using this case as a framework, we discuss the pathophysiological basis of SPENCD, the spectrum and treatment challenges of its associated autoimmune cytopenias, and the evolving role of targeted therapies in monogenic interferonopathies, with particular emphasis on SPENCD, and summarize the published experience with anifrolumab in these disorders. Collectively, this case and the available literature provide preliminary support for IFNAR1 blockade as a mechanism-based, steroid-sparing strategy for refractory autoimmune cytopenias in SPENCD."
Journal • Review • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Inflammatory Arthritis • Interferonopathies • Lupus • Orthopedics • Systemic Lupus Erythematosus • IFNAR1 • TRAP
|
|
Cátia Duarte; Maria João Cadório
|